Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea

Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea

Background The efficacy and safety of denosumab have been established in a phase 3, randomized, placebo-controlled trial in Korean postmenopausal women with osteoporosis. This postmarketing surveillance study was aimed to investigate the safety and effectiveness of denosumab in Korean real-world cli...

Full description

Bibliographic Details
Main Authors:	Yumie Rhee, Dong-Gune Chang, Jeonghoon Ha, Sooa Kim, Yusun Lee, Euna Jo, Jung-Min Koh
Format:	Article
Language:	English
Published:	Korean Endocrine Society 2022-06-01
Series:	Endocrinology and Metabolism
Subjects:	bone density denosumab osteoporosis postmarketing drug surveillance safety korea
Online Access:	http://www.e-enm.org/upload/pdf/enm-2022-1427.pdf

Similar Items

Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea
by: Seungju Cha, et al.
Published: (2024-01-01)

Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study
by: Chaiho Jeong, et al.
Published: (2023-04-01)

The efficacy of denosumab in Korean male patients with osteoporosis
by: Chaiho Jeong, et al.
Published: (2022-09-01)

Effect of Denosumab on Bone Density in Postmenopausal Osteoporosis: A Comparison with and without Calcium Supplementation in Patients on Standard Diets in Korea
by: Chaiho Jeong, et al.
Published: (2023-11-01)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
by: Radosław Słopień, et al.
Published: (2017-10-01)

Correction: Efficacy of Denosumab in the Treatment of Postmenopausal Osteoporosis: One-year Follow-up, Single Center Study
by: İsmail Tunçekin, et al.
Published: (2023-12-01)

Effectiveness of Denosumab in Postmenopausal Osteoporosis Treatment: A 1-yr Follow-up Single-center Study
by: Nihal Tezel, et al.
Published: (2021-12-01)

Long-term consequences of osteoporosis therapy with denosumab
by: Francisco Bandeira, et al.
Published: (2022-12-01)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
by: Yasuaki Hirooka, et al.
Published: (2021-09-01)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
by: Yong-Ki Min
Published: (2015-03-01)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
by: Mingwei Hu, et al.
Published: (2023-07-01)

Denosumab Treatment of Severe Disuse Osteoporosis in a Boy With Spinal Muscular Atrophy
by: Stepan Kutilek
Published: (2017-12-01)

Evaluation of Patient Satisfaction, Back Pain, and Bone Mineral Densitometry T-Scores in Patients with Postmenopausal Osteoporosis Who Received Denosumab Treatment
by: Gonca Sağlam, et al.
Published: (2021-12-01)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
by: Yi Chen, et al.
Published: (2021-04-01)

Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
by: Yanbeiy ZA, et al.
Published: (2019-08-01)

Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
by: Lianghai Jiang, et al.
Published: (2022-11-01)

Osteoporosis in men: epidemiology and treatment with denosumab
by: Sidlauskas KM, et al.
Published: (2014-04-01)

A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis
by: Shailesh Pitale, et al.
Published: (2015-01-01)

Denosumab treatment for osteopenia or osteoporosis in heart transplant recipients: Effects and safety
by: Juan C. Uzquiano, et al.
Published: (2022-09-01)

Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis
by: Uehara M, et al.
Published: (2018-05-01)

Denosumab for the treatment of HIV-associated osteoporosis with fractures in a premenopausal woman
by: E. Marasco, et al.
Published: (2021-04-01)

Discontinuation of Denosumab: Gradual Decrease in Doses Preserves Half of the Bone Mineral Density Gain at the Lumbar Spine
by: Michel Laroche, et al.
Published: (2023-07-01)

Efficacy of denosumab therapy for a 12-year-old female patient with Williams syndrome with osteoporosis and history of fractures: a case report
by: Masashi Uehara, et al.
Published: (2021-12-01)

EFFECT OF DENOSUMAB ON CLINICAL AND RADIOLOGICAL CHANGES IN RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS
by: P. S. Dydykina, et al.
Published: (2015-04-01)

Denosumab for the treatment of osteoporosis
by: Michael R. McClung
Published: (2017-03-01)

Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study
by: Jiemei Gu, et al.
Published: (2023-01-01)

Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice
by: O. V. Dobrovolskaya, et al.
Published: (2019-05-01)

Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab
by: Zhanna E. Belaya, et al.
Published: (2018-04-01)

Efficacy of denosumab therapy for a 21-year-old woman with Prader-Willi syndrome, osteoporosis and history of fractures: a case report
by: Uehara M, et al.
Published: (2019-02-01)

Does the VDR gene polymorphism influence the efficacy of denosumab therapy in postmenopausal osteoporosis?
by: Anna Wawrzyniak, et al.
Published: (2023-01-01)

THREE YEARS' EXPERIENCE WITH THE BIOLOGICAL AGENT DENOSUMAB USED TO TREAT WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS: EFFICACY, SAFETY AND TREATMENT ADHERENCE
by: N. V. Toroptsova, et al.
Published: (2017-07-01)

Denosumab treatment in patients with different courses of osteoporosis
by: Liudmila Ya. Rozhinskaya, et al.
Published: (2017-12-01)

Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment
by: Nakamura Y, et al.
Published: (2017-10-01)

Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
by: Ning Zhang, et al.
Published: (2020-05-01)

A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial
by: Chia-Che Lee, et al.
Published: (2021-09-01)

Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis
by: Suzuki T, et al.
Published: (2018-12-01)

Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis
by: Filippo Migliorini, et al.
Published: (2021-08-01)

Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab
by: Claudia Kobel, et al.
Published: (2019-10-01)

Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
by: Athanasios D. Anastasilakis, et al.
Published: (2023-09-01)

Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
by: Wei Lin Tay, et al.
Published: (2022-04-01)